Skip to content
MarketScale
‹ Back to IndustriesSciences

New Nuclear Reactors Make Progress in U.S. The Permitting Process Still Keeps Us Behind.

The global energy landscape is undergoing significant changes, and in the midst of this transformation, the role of nuclear power is being revisited with renewed vigor. The advent of small modular nuclear reactors (SMRs) promises a safer, less waste-intensive, and cost-effective approach to nuclear energy, with major international players developing their own footprint of…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Daniel Litwin · ColoradoGeorgiaNuclear EnergyNuclear Reactors
Share

Key takeaways

01

The global energy landscape is undergoing significant changes, and in the midst of this transformation, the role of nuclear power is being revisited with renewed vigor.

02

The advent of small modular nuclear reactors (SMRs) promises a safer, less waste-intensive, and cost-effective approach to nuclear energy, with major international players developing their own footprint of…

Get featured

Want to get featured in MarketScale Sciences?

Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.

Start free

The global energy landscape is undergoing significant changes, and in the midst of this transformation, the role of nuclear power is being revisited with renewed vigor. The advent of small modular nuclear reactors (SMRs) promises a safer, less waste-intensive, and cost-effective approach to nuclear energy, with major international players developing their own footprint of SMRs. What recent progress is the U.S. making on new deployment of nuclear reactors and general nuclear energy developments?

Public support for nuclear power in the U.S. is reaching new heights, with a recent Gallup survey revealing that 55% of adults now back the energy source, the highest figure since 2012. With no carbon emissions and greater consistency than renewable sources like wind and solar, nuclear power is increasingly recognized for its reliability, leading the Biden administration to champion nuclear energy, particularly “advanced nuclear” reactors with enhanced safety and efficiency features, as a key strategy in achieving a stable, net-zero emissions future.

Projects and research surrounding deployment of nuclear reactors are gaining traction in the U.S., too, some new and some several years in the making. Colorado, for example, is close to deploying research funds toward nuclear energy projects as part of its “Assess Advanced Energy Solutions in Rural Colorado”. Southern Co.’s Vogtle nuclear project in Georgia, despite being seven years overdue and $16 billion over budget, is also nearing completion and is set to become the largest single power source in the U.S. Although currently no other U.S. company plans a project on Vogtle’s scale, experts suggest this could change with up to five similar reactors potentially being built in the next 35 years.

Still, though, if the U.S. is serious about nuclear energy adoption, certain red tape will need to get cut for getting new sites developed and in time to meet the country’s and world’s climate goals. Sarah Kurtz, professor at UC Merced’s School of Engineering and a renowned next-gen energy researcher and expert, gives her analysis of the current conversations surrounding nuclear energy’s return and the promise for future deployment of nuclear reactors.

Sarah’s Thoughts on Development of U.S. Nuclear Reactors 

“In my class this semester, we had debates about nuclear power with opinions ranging from no way to nuclear is a great option. We found that the promises made for the new small modular nuclear reactors are like a dream come true. No worry of a meltdown, hazardous waste reduced or eliminated, lower costs by being assembled cookie cutter fashion, much like prefab houses. So is this hype or is it real?

Small modular reactors are progressing at a snail’s pace in the U.S., but China has already one operating and a second planned. China is also implementing this technology in developing countries like Argentina. In the U.S., the permitting process effectively blocks nuclear. In developing countries, the need for reliable power enables permitting and a much shorter timeline. From what I’ve read, China’s likely to be a leader with small modular reactors.

I expect that not all of the promises will be realized, but small modular nuclear reactors are making good progress. While large scale nuclear is stalled in the U.S., alongside of solar and wind, small nuclear reactors are worth looking at for the future. There’s a snag or problem with every energy solution, but together the solutions we have on the table can deliver a much better world than what we have today. We have to stop being against the things we aren’t 100% for.”

Article written by Daniel Litwin.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

Daniel Litwin
Daniel LitwinEditor, B2B Media, MarketScale

Daniel Litwin is a journalist of multiple disciplines focused on finding and telling engaging stories for B2B communities. He has interviewed executives from Fortune 500 companies including Honeywell, Microsoft, John Deere, and Chipotle, and leads editorial direction at MarketScale. Litwin hosts weekly shows and podcasts while helping develop new content approaches across the MarketScale platform. He holds a B.J. in Radio/Television Reporting/Anchoring and a B.A. in Spanish from the University of Missouri-Columbia.

Follow Sciences Insights

Get new expert content in your inbox.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Sciences Insights

Pharma supplier diversification means little if every supplier uses the same airport

Pharma supplier diversification means little if every supplier uses the same airport

Biocair's Patrick Wohl argues in Pharmaceutical Commerce that life sciences firms must map airports, sea lanes, customs gateways and carriers alongside suppliers. Suppliers spread across countries can still share one air hub. The fix he describes is pre-qualified alternate routes and continuous review, with clinical trial shipments and cold-chain medicines the first cargo exposed when a corridor closes.

  • 01A supplier base spread across several countries can still be a single point of failure if every shipment routes through one airport hub or corridor; the sharper question for a logistics provider is which hubs each qualified lane actually depends on.
  • 02Gartner data cited by MD+DI gives a benchmark: 42% of procurement leaders rank supply disruption as their organization's top risk, with geopolitical issues including tariffs and regulatory changes ranking third.
  • 03A route map ages fast. Pharmaceutical Commerce published the mapping argument on July 24 and was reporting fresh Red Sea and Iran-related freight risk for pharma lanes by Aug. 10, which is the case for treating mapping as a recurring review rather than a project.

Sep 17, 2026

Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply

Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply

Resilience and Eli Lilly are investing $750 million to expand KwikPen injectable device production at Resilience's Cincinnati-region manufacturing facility, expected to create 400 high-skilled jobs and reach full operations by early 2027. The partnership builds on their collaboration since 2023, which has already produced over 150 million doses of Lilly medications for the U.S. market.

  • 01$750 million investment to expand Resilience's Ohio manufacturing capacity for Eli Lilly's KwikPen injectable device production
  • 02400 new high-skilled jobs expected in Cincinnati region, with full operations by early 2027
  • 03Partnership has already produced over 150 million doses of Lilly medications for the U.S. market since 2023

Sep 14, 2026

ENEOS ran an AI controller on a distillation column for 35 days and cut steam use 40%

ENEOS ran an AI controller on a distillation column for 35 days and cut steam use 40%

ENEOS Materials and Yokogawa ran an autonomous AI controller on a butadiene distillation column for 35 days and cut steam use 40%. It’s a real operations proof point. It also puts integration and governance gaps front and center.

  • 01A 35-day closed-loop run is a stronger autonomy proof point than a demo, it forces plants to prove handover, fallback, and KPIs over real feed and operating swings.
  • 02Steam reduction claims are compelling, but procurement and ops teams should pin vendors to baselines, operating envelopes, and how off-spec avoidance is measured.
  • 03Agentic AI is showing up as “work management” and “shift checklist” agents before it replaces control engineers, which shifts requirements toward clean, permissioned data access.

Sep 13, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

Daniel Litwin
Daniel Litwin

Editor, B2B Media

MarketScale

Daniel Litwin is a journalist of multiple disciplines focused on finding and telling engaging stories for B2B communities. He has interviewed executives from Fortune 500 companies including Honeywell, Microsoft, John Deere, and Chipotle, and leads editorial direction at MarketScale. Litwin hosts weekly shows and podcasts while helping develop new content approaches across the MarketScale platform. He holds a B.J. in Radio/Television Reporting/Anchoring and a B.A. in Spanish from the University of Missouri-Columbia.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512